Why the study?
Does Transcatheter Aortic-Valve Replacement (TAVR) improve mortality, symptoms, and valve hemodynamics compared to Surgical Aortic-Valve Replacement in high-risk patients?
Does Transcatheter Aortic-Valve Replacement (TAVR) improve mortality, symptoms, and valve hemodynamics compared to Surgical Aortic-Valve Replacement in high-risk patients?
TAVR remains viable for high-risk patients; extends evidence by linking paravalvular regurgitation to late mortality.
A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative to surgery in high-risk patients. The two treatments were similar with respect to mortality, reduction in symptoms, and improved valve hemodynamics, but paravalvular regurgitation was more frequent after TAVR and was associated with increased late mortality. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).
No takes yet. Share an insight, caveat, or question.
Kodali et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: